PreprintArticleVersion 1This version is not peer-reviewed
Elacestrant Plus Alpelisib in an ESR1 and PIK3CA Co-mutated and Heavily Pretreated Metastatic Breast Cancer: The First Case for Combination Efficacy and Safety
Version 1
: Received: 1 August 2024 / Approved: 2 August 2024 / Online: 2 August 2024 (03:52:29 CEST)
How to cite:
Tokat, Ü. M.; Bilgiç, Ş. N.; Aydın, E.; Adibi, A.; Özgü, E.; Tutar, O.; Demiray, M. Elacestrant Plus Alpelisib in an ESR1 and PIK3CA Co-mutated and Heavily Pretreated Metastatic Breast Cancer: The First Case for Combination Efficacy and Safety. Preprints2024, 2024080128. https://doi.org/10.20944/preprints202408.0128.v1
Tokat, Ü. M.; Bilgiç, Ş. N.; Aydın, E.; Adibi, A.; Özgü, E.; Tutar, O.; Demiray, M. Elacestrant Plus Alpelisib in an ESR1 and PIK3CA Co-mutated and Heavily Pretreated Metastatic Breast Cancer: The First Case for Combination Efficacy and Safety. Preprints 2024, 2024080128. https://doi.org/10.20944/preprints202408.0128.v1
Tokat, Ü. M.; Bilgiç, Ş. N.; Aydın, E.; Adibi, A.; Özgü, E.; Tutar, O.; Demiray, M. Elacestrant Plus Alpelisib in an ESR1 and PIK3CA Co-mutated and Heavily Pretreated Metastatic Breast Cancer: The First Case for Combination Efficacy and Safety. Preprints2024, 2024080128. https://doi.org/10.20944/preprints202408.0128.v1
APA Style
Tokat, Ü. M., Bilgiç, Ş. N., Aydın, E., Adibi, A., Özgü, E., Tutar, O., & Demiray, M. (2024). Elacestrant Plus Alpelisib in an ESR1 and PIK3CA Co-mutated and Heavily Pretreated Metastatic Breast Cancer: The First Case for Combination Efficacy and Safety. Preprints. https://doi.org/10.20944/preprints202408.0128.v1
Chicago/Turabian Style
Tokat, Ü. M., Onur Tutar and Mutlu Demiray. 2024 "Elacestrant Plus Alpelisib in an ESR1 and PIK3CA Co-mutated and Heavily Pretreated Metastatic Breast Cancer: The First Case for Combination Efficacy and Safety" Preprints. https://doi.org/10.20944/preprints202408.0128.v1
Abstract
Breast cancer (BC) is the leading cause of cancer-related mortality among women, and hormone receptor (HR)-positive subtype makes up majority of all cases. The standard-of-care (SOC) in HR+/HER2- metastatic BC (MBC) is endocrine therapy (ET) plus a CDK4/6 inhibitor (CDK4/6i). ESR1 mutations could impair clinical efficacy of the ETs. Similarly, PIK3CA mutations may serve as a negative prognostic marker. Furthermore, MBC is challenging to treat despite new drug approvals. Our patient received multiple lines of ET ± CDK4/6i and chemotherapy but persistently progressed after each or stopped the treatment due to adverse events. Here we showed for the first time that all-oral combination of elacestrant plus alpelisib was feasible, tolerable and clinically active in an ESR1 and PIK3CA co-mutated and heavily pretreated patient. We achieved a remarkable response in the metastatic lesions with minor toxicity issues. This case highlights the importance of utilizing up-to-date therapeutic agents and reactive decision-making during personalized cancer treatment.
Keywords
HR+/HER2- metastatic breast cancer; HR-positive; Selective estrogen receptor degrader (SERD); Elacestrant; Alpelisib; Precision oncology; Cancer genomics
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
